Exploring Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Diagnostic Best Practices and Considerations in Addressing Underlying Inflammation

Sunday, February 27, 2022


8:15 AM – 9:30 AM Eastern

7:15 AM – 8:30 AM Central

6:15 AM – 7:30 AM Mountain/Arizona

5:15 AM – 6:30 AM Pacific


  • Online personalized quality-improvement poster-generation portal
  • Downloadable whiteboard animations

This program is not sponsored or programmed by the AAAAI.


I. Introduction
 a. Burden of moderate-to-severe CRSwNP
 b. Brief review of therapeutic developments
 c. Inflammatory pathophysiology and the need to address
 d. Underlying inflammation
 e. Recognizing recent approvals and the latest clinical data in CRSwNP

II. Pathophysiologic and Diagnostic Considerations in CRSwNP
 a. Pathophysiology
  • Role of inflammation
  • Th2 predominant inflammatory pattern, associated endotypes, and biomarkers
 b. Establishing a diagnosis of CRSwNP
  • Mild, moderate, and severe disease
  • Guidelines for management and upcoming changes with availability of biologics
  • Biomarkers
  • Role of allergists and otolaryngologists
 c. Clinical data
  • Key clinical trials (LIBERTY NP SINUS-24, LIBERTY NP SINUS-52, POLYP-1 and POLYP-2, etc)
  • Clinical efficacy considerations with management of comorbid conditions
  • Safety
 d. Animation: Targeting the Underlying Pathophysiology of CRSwNP in Patients with Moderate to
  Severe Disease

III. Optimizing Interdisciplinary Care Management of CRSwNP
 a. Interdisciplinary collaboration and management
 b. Comorbidities
 c. Shared decision-making
  • Best practices for considering systemic biologic therapy in CRSwNP
  • How best to discuss treatment with patients
 d. Animation: Best Practices for Interdisciplinary Care and Shared Decision-Making in CRSwNP
 e. Cases demonstrating important gaps in therapy

IV. Conclusions

Learning Objectives

  • Define the burden and pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Evaluate clinical data and biomarkers concerning the use of novel anti-inflammatory biologics for the management of CRSwNP
  • Apply best practices for the interdisciplinary development of individualized treatment plans for patients with CRSwNP

Target Audience

This activity is designed to meet the educational needs of allergists, otolaryngologists, primary care physicians, nurses, nurse practitioners, pharmacists, and other members of the multidisciplinary team to ensure an up-to-date understanding of the latest data in management of chronic rhinosinusitis with nasal polyps.

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Release date: February 27, 2022
Expiration date: February 27, 2022
Estimated time to completion: 2.0 hours